Page 132 - 《中国药房》2024年23期

MÁÑEZ R. Mesoporous silica nanoparticles for pulmo‐ cancer targeting and theranostic application[J]. Biochim
nary drug delivery[J]. Adv Drug Deliv Rev，2021，177： Biophys Acta Gen Subj，2021，1865（9）：129936.
113953. [23] GONZALEZ T，MUMINOVIC M，NANO O，et al. Folate
[10] FENG X J，SHI Y，ZHANG Y，et al. Opportunities and receptor alpha：a novel approach to cancer therapy[J]. Int J
challenges for inhalable nanomedicine formulations in re‐ Mol Sci，2024，25（2）：1046.
spiratory diseases：a review[J]. Int J Nanomedicine，2024， [24] ROSIÈRE R，VAN WOENSEL M，GELBCKE M，et al.
19：1509-1538. New folate-grafted chitosan derivative to improve deli-
[11] DENG Y D，ZHANG X D，SHEN H B，et al. Application very of paclitaxel-loaded solid lipid nanoparticles for lung
of the nano-drug delivery system in treatment of cardio‐ tumor therapy by inhalation[J]. Mol Pharm，2018，15（3）：
vascular diseases[J]. Front Bioeng Biotechnol，2019， 899-910.
7：489. [25] ZHU X J，KONG Y，LIU Q，et al. Inhalable dry powder
[12] MIKUŠOVÁ V，MIKUŠ P. Advances in chitosan-based prepared from folic acid-conjugated docetaxel liposomes
nanoparticles for drug delivery[J]. Int J Mol Sci，2021，22 alters pharmacodynamic and pharmacokinetic properties
（17）：9652. relevant to lung cancer chemotherapy[J]. Pulm Pharmacol
[13] LEONG E W X，GE R W. Lipid nanoparticles as delivery Ther，2019，55：50-61.
vehicles for inhaled therapeutics[J]. Biomedicines，2022， [26] HAN L，HUANG R Q，LIU S H，et al. Peptide-conjugated
10（9）：2179. PAMAM for targeted doxorubicin delivery to transferrin
[14] ANDERSON S，ATKINS P，BÄCKMAN P，et al. Inhaled receptor overexpressed tumors[J]. Mol Pharm，2010，7
medicines：past，present，and future[J]. Pharmacol Rev， （6）：2156-2165.
2022，74（1）：48-118. [27] ABDELAZIZ H M，ELZOGHBY A O，HELMY M W，
[15] NSAIRAT H，KHATER D，SAYED U，et al. Liposomes： et al. Inhalable lactoferrin/chondroitin-functionalized mo‐
structure，composition，types，and clinical applications[J]. noolein nanocomposites for localized lung cancer targeting
Heliyon，2022，8（5）：e09394. [J]. ACS Biomater Sci Eng，2020，6（2）：1030-1042.
[16] ZHANG T T，CHEN Y M，GE Y Y，et al. Inhalation treat‐ [28] ZHANG X W，SHAN M R，LI S Y，et al. Investigating
ment of primary lung cancer using liposomal curcumin the trans-membrane transport of HAIYPRH peptide-
dry powder inhalers[J]. Acta Pharm Sin B，2018，8（3）： decorated nano-drugs[J]. Phys Chem Chem Phys，2023，25
440-448. （14）：9766-9771.
[17] PALIWAL R，PALIWAL S R，KENWAT R，et al. Solid [29] RIAZ M K，ZHANG X，WONG K H，et al. Pulmonary de‐
lipid nanoparticles：a review on recent perspectives and livery of transferrin receptors targeting peptide surface-
patents[J]. Expert Opin Ther Pat，2020，30（3）：179-194. functionalized liposomes augments the chemotherapeutic
[18] ABDULBAQI I M，ASSI R A，YAGHMUR A，et al. Pul‐ effect of quercetin in lung cancer therapy[J]. Int J Nano‐
monary delivery of anticancer drugs via lipid-based nano‐ medicine，2019，14：2879-2902.
carriers for the treatment of lung cancer：an update[J]. [30] ROSHANCHESHM S，ASADI A，KHOSHNAZAR S M，
Pharmaceuticals，2021，14（8）：725. et al. Application of natural and modified exosomes a drug
[19] YANG Y，HUANG Z W，LI J Y，et al. PLGA porous mi‐ delivery system[J]. Nanomed J，2022，9（3）：192-204.
crospheres dry powders for codelivery of afatinib-loaded [31] ZHENG W，ZHU T C，TANG L T，et al. Inhalable CAR-T
solid lipid nanoparticles and paclitaxel：novel therapy for cell-derived exosomes as paclitaxel carriers for treating
EGFR tyrosine kinase inhibitors resistant nonsmall cell lung cancer[J]. J Transl Med，2023，21（1）：383.
lung cancer[J]. Adv Healthc Mater，2019，8（23）： [32] BARJAKTAREVIC I Z，MILSTONE A P. Nebulized
e1900965. therapies in COPD：past，present，and the future[J]. Int J
[20] VIEIRA I R S，CONTE-JUNIOR C A. Nano-delivery sys‐ Chron Obstruct Pulmon Dis，2020，15：1665-1677.
tems for food bioactive compounds in cancer：prevention， [33] YAMAMOTO H，KUNO Y，SUGIMOTO S，et al.
therapy，and clinical applications[J]. Crit Rev Food Sci Surface-modified PLGA nanosphere with chitosan im‐
Nutr，2024，64（2）：381-406. proved pulmonary delivery of calcitonin by mucoadhesion
[21] GADAG S，NARAYAN R，NAYAK A S，et al. Develop‐ and opening of the intercellular tight junctions[J]. J Con‐
ment and preclinical evaluation of microneedle-assisted trol Release，2005，102（2）：373-381.
resveratrol loaded nanostructured lipid carriers for locali- [34] MILLER M R，RAFTIS J B，LANGRISH J P，et al. In‐
zed delivery to breast cancer therapy[J]. Int J Pharm， haled nanoparticles accumulate at sites of vascular disease
2021，606：120877. [J]. ACS Nano，2017，11（5）：4542-4552.
[22] RIZWANULLAH M，AHMAD M Z，GARG A，et al. Ad‐ （收稿日期：2024-06-16 修回日期：2024-10-09）
vancement in design of nanostructured lipid carriers for （编辑：唐晓莲）

· 2958 · China Pharmacy 2024 Vol. 35 No. 23 中国药房 2024年第35卷第23期